Company overview
Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for the detection of MRD; and NeXT Dx, a tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. In addition, the company performs whole exome sequencing of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing on human samples for research projects, such as population sequencing initiatives. Its services are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies, and for clinical trials, as well as tests are used by physicians to detect residual or recurrent cancer in patients, monitor cancer response to therapy, and uncover insights for therapy selection. The company's customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company has strategic collaboration with Tempus AI, Inc. to bring ultra-sensitive cancer recurrence testing to colorectal cancer patients. Personalis, Inc. was incorporated in 2011 and is headquartered in Fremont, California.
Daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-08. TTM means trailing twelve months. Use the market date when comparing PSNL with another company.
| Daily close (USD) | $16.06 |
| Market capitalization (USD) | $1,715,205,944.32 |
| Price / earnings (TTM) | Not reported |
| Price / book | 7.29 |
No matching rows. Clear the filter to see all records.
Read PSNL's valuation metrics
Company size
Personalis, Inc. Common Stock's recorded market capitalization is $1,715,205,944.32. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
PSNL's recorded price-to-book ratio is 7.29. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research Personalis, Inc. Common Stock with Aurora
Use the snapshot above to ask a specific question about PSNL. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow PSNL's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.